Last viewed:
MTEM
Prices are updated after-hours
MTEM
|
$1.55
3.33%
3.54%
24K
|
Health Technology
(0.0% 1d)
(-35.1% 1m)
(270.8% 1y)
(0.0% 2d)
(3.3% 3d)
(4.0% 7d)
(-11.07%
volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 8,330,115
http://www.mtem.com
Sec
Filling
|
Patents
| 168 employees
(US) Molecular Templates, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. Molecular Templates was founded by Eric E. Poma, Jean Gariépy and Leigh Revers on October 17, 2001 and is headquartered in Austin, TX.
cancer
treatment
add to watch list
Paper trade
email alert is off
Press-releases
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
Published: 2024-04-09
(Crawled : 12:00)
- globenewswire.com
MTEM
|
$1.55
3.33%
3.54%
24K
|
Health Technology
| -16.22%
| O: 9.73%
H: 0.49%
C: -8.87%
mt-6402
association
tumors
cancer
research
for
molecular
study
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-09
(Crawled : 13:30)
- biospace.com/
MTEM
|
$1.55
3.33%
3.54%
24K
|
Health Technology
| -16.22%
| O: 9.73%
H: 0.49%
C: -8.87%
mt-6402
association
tumors
cancer
research
for
meeting
molecular
study
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
Published: 2024-03-29
(Crawled : 12:30)
- globenewswire.com
MTEM
|
$1.55
3.33%
3.54%
24K
|
Health Technology
| Email alert
Add to watchlist
business
update
financial
results
molecular
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
Published: 2024-03-28
(Crawled : 12:00)
- globenewswire.com
MTEM
|
$1.55
3.33%
3.54%
24K
|
Health Technology
| -34.04%
| O: 18.3%
H: 0.0%
C: -19.42%
million
offering
agreement
molecular
Molecular Templates, Inc. Provides Interim Update
Published: 2024-03-04
(Crawled : 13:00)
- globenewswire.com
MTEM
|
$1.55
3.33%
3.54%
24K
|
Health Technology
| -57.88%
| O: 11.96%
H: 0.0%
C: -6.55%
update
molecular
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-08
(Crawled : 23:00)
- globenewswire.com
MTEM
|
$1.55
3.33%
3.54%
24K
|
Health Technology
| -55.84%
| O: 1.14%
H: 0.0%
C: -1.13%
conference
life
sciences
molecular
Relapsing/Refractory Multiple Myeloma Market to Observe Stupendous Growth by 2032, Estimates DelveInsight | Leading Companies - Bristol-Myers Squibb, Allogene Therapeutics, Genentech, Pfizer, Ionis Pharmaceuticals, AbbVie, Amgen
Published: 2024-01-25
(Crawled : 22:00)
- prnewswire.com
ACLX
|
$54.44
4.69%
4.46%
410K
|
| -8.26%
| O: 0.2%
H: 5.99%
C: 5.65%
JNJ
|
News
|
$149.56
0.3%
-0.17%
6.9M
|
Health Technology
| -5.93%
| O: 0.8%
H: 0.0%
C: 0.0%
MTEM
|
$1.55
3.33%
3.54%
24K
|
Health Technology
| -58.56%
| O: -2.94%
H: 3.03%
C: 3.03%
IONS
|
$41.84
1.88%
1.86%
630K
|
Health Technology
| -18.88%
| O: 0.43%
H: 0.27%
C: -0.6%
INCY
|
$51.65
-0.52%
-0.58%
2.5M
|
Health Technology
| -15.22%
| O: 0.66%
H: 0.64%
C: -1.11%
IMAB
|
$1.8
0.55%
200K
|
Health Technology
| -0.55%
| O: 1.1%
H: 0.27%
C: -1.64%
companies
growth
market
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
Published: 2023-11-13
(Crawled : 21:00)
- globenewswire.com
MTEM
|
$1.55
3.33%
3.54%
24K
|
Health Technology
| -72.32%
| O: -3.75%
H: 5.16%
C: 1.3%
business
update
financial
results
molecular
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
Published: 2023-11-02
(Crawled : 20:00)
- globenewswire.com
MTEM
|
$1.55
3.33%
3.54%
24K
|
Health Technology
| -68.43%
| O: 8.15%
H: 1.13%
C: -5.65%
mt-8421
tumors
trial
molecular
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
Published: 2023-11-02
(Crawled : 12:00)
- globenewswire.com
VTVT
|
$24.975
2.21%
0.35%
4.4K
|
Health Technology
| 52.28%
| O: -0.02%
H: 2.44%
C: -2.37%
OMER
|
$3.09
0.33%
0.0%
210K
|
Health Technology
| 173.45%
| O: 1.77%
H: 6.96%
C: 6.09%
MTEM
|
$1.55
3.33%
3.54%
24K
|
Health Technology
| -69.0%
| O: 3.5%
H: 0.0%
C: -5.12%
medical
therapeutics
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0000950170-24-042010
4
2024-04-05
2024-04-02
Buy
P
769334
769334
0000950170-24-042010
4
2024-04-05
2024-04-02
Buy
P
134667
134667
0000950170-24-042010
4
2024-04-05
2024-04-02
Buy
P
250000
1279820
0001415889-24-010303
4
2024-04-04
2024-04-02
Buy
A
1154154
1154154
0001415889-24-010303
4
2024-04-04
2024-04-02
Buy
A
402077
402077
0001415889-24-010303
4
2024-04-04
2024-04-02
Buy
A
175000
175000